Brief: Longboard Pharmaceuticals Q2 basic EPS USD -0.65
03/08/2023 22:13
Aug 3 (Reuters) - Longboard Pharmaceuticals Q2 basic EPS USD -0.65. * Q2 net income USD -14.999 million * Q2 operating expenses USD 15.642 million * Q2 income from operations USD -15.642 million
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions